InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage biopharmaceutical company developing therapeutics targeting diseases with high unmet medical needs, today revealed the rare cannabinoid  cannabinol (“CBN”) as the active pharmaceutical ingredient (“API”) in its two product candidates under development: INM-755 for epidermolysis bullosa (“EB”) and INM-088 for glaucoma.…
Read More